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Objectives The purpose of this study was to develop a new intelligent drug delivery system for intracoronary thrombolysis
with a strong thrombolytic effect without increasing bleeding risk.
Background Rapid recanalization of an occluded coronary artery is essential for better outcomes in acute myocardial infarc-
tion. Catheter-based recanalization is widely accepted, but it takes time to transport patients. Although the cur-
rent fibrinolytic therapy can be started quickly, it cannot achieve a high reperfusion rate. Recently, we generated
nanoparticles comprising tissue-type plasminogen activator (tPA), basic gelatin, and zinc ions, which suppress
tPA activity by 50% with 100% recovery by ultrasound (US) in vitro.
Methods The thrombus-targeting property of nanoparticles was examined by an in vitro binding assay with von Wilbrand
factor and with a mouse arterial thrombosis model in vivo. The thrombolytic efficacy of nanoparticles was evalu-
ated with a swine acute myocardial infarction model.
Results Nanoparticles bound to von Wilbrand factor in vitro and preferentially accumulated at the site of thrombus in a
mouse model. In a swine acute myocardial infarction model, plasma tPA activity after intravenous injection of
nanoparticles was approximately 25% of tPA alone and was recovered completely by transthoracic US (1.0 MHz,
1.0 W/cm2). During US application, plasma tPA activity near the affected coronary artery was recovered and was
higher than that near the femoral artery. Although treatment with tPA alone (55,000 IU/kg) recanalized the oc-
cluded coronary artery in only 1 of 10 swine, nanoparticles containing the same dose of tPA with US achieved
recanalization in 9 of 10 swine within 30 min.
Conclusions We developed an intelligent drug delivery system with promising potential for better intravenous coronary
thrombolysis. (J Am Coll Cardiol 2012;60:2550–7) © 2012 by the American College of Cardiology Foundation
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accepted August 12, 2012.In the treatment of acute myocardial infarction (AMI), rapid
coronary recanalization is essential for reducing infarct size and
preserving cardiac function, leading to better prognosis. Al-
though percutaneous coronary intervention is accepted as the
appropriate emergent therapy because of its ability to achieve
reliable recanalization, it takes time for transportation of
See page 2558
patients to specialized hospitals, where cardiac catheter-
ization can be performed. However, intravenous pharma-
cological thrombolysis is noninvasive, less expensive, and
simpler than percutaneous coronary intervention and
theoretically can be started immediately after an AMI is
identified, even in an ambulance. With this approach,
however, only 60% to 75% of patients achieve Throm-
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recanalization (1– 4), which is very low in comparison
with the rates accompanying percutaneous coronary
intervention. There are also risks of hemorrhagic
complications.
Accordingly, to enhance thrombolysis, many investigators,
ncluding our group, have combined locally applied ultrasound
US) and thrombolytic agents (sonothrombolysis), and have
emonstrated its efficacy in experimental animals (5–7). How-
ver, a recent clinical study testing the efficacy of sonothrom-
olysis in AMI patients failed to show its superiority to
onventional thrombolytic methods, both in terms of the
ecanalization rate and the occurrence of hemorrhagic compli-
ations (8).
Therefore, the new strategy that coronary recanaliza-
ion therapy could be started immediately after the arrival
f emergent medical services should be developed, such as
n intelligent drug delivery system (DDS) for better
hrombolysis, which encapsulates the thrombolytic
gents to suppress their activity within the systemic
irculation (stealth activity), delivers the encapsulated
gents preferentially to the thrombus (thrombus target-
ng), releases the agents (controlled activity), and conse-
uently facilitates local thrombolytic activity without
ystemic bleeding risk.
Given that fibrillar collagen binds to von Willebrand
actor (vWF), which is expressed on the surface of
latelets (9,10) and is a key component of platelet-rich
hrombi, we took note of gelatin as the material of DDS
ncapsulating the thrombolytic agent for targeting the
hrombus, because gelatin is produced by partial hydro-
ysis of collagen. Recently, we had developed a novel
DS, comprising tissue-type plasminogen activator
tPA), basic gelatin, and zinc ions that suppresses tPA
ctivity, but is recovered by US in vitro (11). In the
resent study, we show that this DDS has stealth activity,
s US controlled in vivo, and has thrombus-targeting
roperties in vitro and in vivo, thus demonstrating the
ntelligent design of this DDS. Furthermore, we evalu-
ted the efficacy of this intelligent DDS on intravenous
oronary thrombolysis in a swine model of AMI.
ethods
detailed Methods section is available in the Online Appendix.
reparation of the nanoparticles encapsulating tPA.
riefly, basic gelatin (100,000 MW, Nitta Gelatin, Inc.,
saka, Japan) and tPA (monteplase, Cleactor Injection,
isai Co., Ltd., Tokyo, Japan) were mixed at the concen-
ration of 20 mg/ml and 1.0 mg/ml, respectively, in 10 mM
hosphate-buffered saline (pH 7.4). After agitation, zinc
cetate (Nacalai Tesque, Inc., Kyoto, Japan) was added to
he mixture of basic gelatin and tPA (at a final concentration
f 5 mM) to stabilize and tighten their connection
Fig. 1A). mAssay of tPA activity in vitro
and in vivo. To determine tPA
activity in vitro, a fibrin clot lysis
assay was performed on the basis
of the plasminogen-rich fibrin
plate method (12,13). The
plasma tPA activity of rabbit and
swine was measured with the
synthetic substrate, chromozym
tPA, according to the manufac-
turer’s instructions (Roche Ap-
plied Science, Indianapolis, USA).
In vitro vWF binding assay.
To evaluate whether vWF pro-
tein binds to tPA, basic gelatin,
or nanoparticles, an enzyme im-
munoassay was performed with
the use of rabbit antihuman vWF
antibody (DAKO, Glostrup,
Denmark).
Evaluation of tPA accumulation
in the occluded vessel. For the evaluation of tPA accumu-
lation at the thrombus site in the mouse arterial thrombosis
model induced by ferric chloride methods, tPA was radio-
iodinated with iodide 125 (125I) according to the chloramine
method (14).
125I-labeled tPA alone (27,500 IU/kg; 0.2235 mg/kg)
or nanoparticles containing the same dose of 125I-labeled
PA (n  5 for each) in 100 l phosphate-buffered saline
ere injected into the tail vein of the mouse 30 minutes
fter the induction of thrombotic occlusion in the left
emoral artery (FA). Ten minutes later, the bilateral
liofemoral arteries at 2 cm length were excised, along
ith the blood inside the lumen, after ligation of both
nds and all branches. The radioactivity of the iliofemoral
rtery was counted with a gamma counter (ARC-301B,
loka, Tokyo, Japan).
eneration and evaluation of the transthoracic US device.
n the basis of the in vitro and rabbit experiments, we
ested US probes of 3 different frequencies (0.5, 1.0, and
.0 MHz) and 1.0 W/cm2 in intensity. Four US probes of
each frequency were combined in parallel to generate
continuous-wave transthoracic US (TUS) devices for the
swine model, as shown in Online Figure 1. Only the
1.0-MHz frequency (continuous wave, 1.0 W/cm2) de-
ice produced relatively uniform US fields both in a water
ath test (data not shown) and over the swine heart, as
uantified by an oscilloscope (Online Fig. 2).
reparation of the swine AMI model. For the preparation
f the swine AMI model, thrombotic occlusion of the left
ircumflex coronary artery (LCx) was induced in 60 female
wine (35 to 45 kg) by balloon injury with distal balloon
cclusion, as shown in Online Figure 3.
hrombolysis in the swine AMI model. Thrombolysis
as initiated by the injection of 27,500 IU/kg (0.2235
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
DDS  drug delivery
system
FA  femoral artery
LCx  left circumflex
coronary artery
TIMI  Thrombolysis In
Myocardial Infarction
tPA  tissue-type
plasminogen activator
TUS  transthoracic
ultrasound
US  ultrasound
vWF  von Willebrand
factor
125I  iodide 125g/kg) or 55,000 IU/kg (0.447 mg/kg) tPA, or nano-
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over 5 min. Subsequently, continuous-wave US (1.0
MHz, 1.0 W/cm2) was applied transthoracically in the
cases with TUS for up to 60 minutes (n  10 for each
treatment).
Evaluation of left ventricular ejection fraction after
thrombolysis. At 60 min after the initiation of thrombol-
ysis, left ventriculography at the left anterior oblique view
was performed, and left ventricular ejection fraction was
calculated.
Statistical analysis. Data were expressed as mean  SD.
Data distribution was assessed for normality by using the
Kolmogorov-Smirnov test. Normally distributed data
were analyzed by paired or unpaired Student t tests for
2-group comparisons and 1-factor analyses of variance
with Fisher Protected Least Significant Difference cor-
rection for multigroup comparisons. Nonnormally dis-
tributed data were compared between groups by using the
Kruskal-Wallis analysis and subsequent Mann-Whitney
U test for multiple comparisons. The ratios of TIMI flow
grade 2 and TIMI flow grade 3 in thrombolysis at each
time point were compared between groups by using the
Fisher exact test, and adjusted multiple comparisons for
intergroup differences in the data of thrombolysis over
the time course were not performed. Values of p 0.05
zinc acetate (5 mM)
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Figure 1 Images and Properties of Nanoparticles
(A) Schematic showing the assembly of nanoparticles (NP) composed of tissue-typ
(micrograms per milliliter equivalent) immediately and 5 minutes after injection of
transcutaneous US application (**p  0.01). (C) Binding ability of tPA, basic gela
density (OD) measured at the wavelength of 492 nm (**p  0.01 vs. tPA). (D) Ra
of 125I-labeled tPA or NP containing the same dose of 125I-labeled tPA. Data are e
artery (**p  0.01 vs. injection of 125I-labeled tPA). ab  rabbit anti-human vWF awere considered to indicate statistical significance. UResults
Schema of the new intelligent DDS. Figure 1A shows
the schema of the intelligent DDS, which is character-
ized by both its thrombus-targeting property and its
stealth activity of tPA reactivated by US. The nanopar-
ticles are prepared by adding zinc acetate (final concen-
tration, 5 mM) into the mixture of tPA and basic gelatin
at concentrations of 0.5 mg/ml and 10 mg/ml, respec-
tively. The nanoparticles are approximately 100 nm in diam-
eter as measured by the dynamic light scattering method (13).
tPA is released from the nanoparticles by application of US
(continuous wave, 1.0 MHz, and 1.0 W/cm2).
PA activity of the intelligent DDS in vivo. tPA activity
as reduced by approximately 50% by the nanoparticle
ormulation, but was fully recovered by US application in
itro (Online Fig. 4) (11). In the present study, decreased
PA activity of the nanoparticles also was confirmed in
abbits. Plasma tPA activity immediately after nanoparticle
njection was 71.4% lower than that after injection of the
ame dose of free tPA (Fig. 1B). Five minutes after the
ranscutaneous US application, tPA activity of the nanopar-
icles at the site of US application was recovered to the level
imilar to that after free tPA injection. Additionally, plasma
PA activity of the nanoparticles also was recovered by the
noparticle (NP)
(100-150 nm)
tPA releasing
US (1 MHz, 1 W/cm2)
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(Online Fig. 5).
Binding ability of the nanoparticles to vWF in vitro. To
design nanoparticles to target sites with thrombus, we adopted
basic gelatin, a heat-denatured collagen, because collagen binds
to vWF, a key component of platelet-rich thrombi. As shown
in Figure 1C, the binding ability of basic gelatin (106 M) and
the nanoparticles (106 M) to vWF was as strong as that of
ntihuman vWF antibody (108 M).
Thrombus-targeting property of nanoparticles. Next, we
evaluated whether nanoparticles target thrombi using
radiolabeled tPA in vivo. Free 125I-labeled tPA alone or
nanoparticles containing the same dose of 125I-labeled
PA were injected into the tail vein of a mouse with
hrombotic occlusion in the left FA. The ratio of radio-
ctivity of the thrombosed left FA to the control right FA
as approximately 3-fold higher in the mice treated with
he nanoparticles than in the mice treated with tPA alone
Fig. 1D), indicating that the nanoparticles have a higher
ffinity for thrombus than free tPA.
hrombolytic efficacy of the intelligent DDS in a swine
MI model. Figure 2 shows the results of thrombolysis in
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Figure 2 Results of Thrombolysis in Swine Acute Myocardial In
(A) Time course of Thrombolysis In Myocardial Infarction (TIMI) flow grade 2 or mo
(squares), and drug delivery system (DDS) (circles) after injection of tPA or nanop
plus TUS). (B) Percentage of TIMI flow grade 2 or more at 30 min and 60 min in s
sent the percentage of TIMI flow grade 2, and closed bars represent the percenta
with 55,000 IU/kg of tPA (*p  0.05 and **p  0.01). (D) Time course of TIMI fl
(squares), and DDS (circles) after injection of tPA or nanoparticles at the dose of
TUS). (E) Percentage of TIMI flow grade 2 or more at 30 min and 60 min in swine
percentage of TIMI flow grade 2, and closed bars represent the percentage of TIM
treated with 27,500 IU/kg of tPA (*p  0.05 and **p  0.01). Abbreviations ashe swine AMI model. In the cases using the intelligentDS (intravenous injection of the nanoparticles contain-
ng 55,000 IU/kg [0.447 mg/kg] tPA followed by TUS
pplication), thrombolysis with TIMI flow grade 2 or
ore was achieved in 9 of 10 swine within 30 min. In
ontrast, only 4 of 10 swine treated with 55,000 IU/kg
0.447 mg/kg) of tPA followed by TUS application (tPA
lus TUS) and only 1 of 10 swine treated with 55,000
U/kg (0.447 mg/kg) of tPA alone (Figs. 2A and 2B)
chieved the same degree of flow. The intelligent DDS
ad a higher rate of TIMI flow grade 3 recanalization
ithin 30 min (60%) in comparison with tPA plus TUS
30%) or tPA alone (0%) (Fig. 2B). Comparing the mean
IMI grade at 30 min among 3 groups, it was signifi-
antly higher in the swine treated with the intelligent
DS containing 55,000 IU/kg (0.447 mg/kg) of tPA
han those treated with 55,000 IU/kg (0.447 mg/kg) tPA
lus TUS or 55,000 IU/kg (0.447 mg/kg) tPA alone
2.50  0.71 vs. 1.30  1.34, p  0.05, and 0.40  0.70,
p  0.01, respectively) (Fig. 2C).
Unexpectedly, in the swine AMI model, low-dose tPA
alone (27,500 IU/kg, 0.2235 mg/kg), equivalent to the
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rate 60% (15), did not recanalize at all up to 60 min after
the initiation of treatment. However, the intelligent
DDS with 27,500 IU/kg (0.2235 mg/kg) tPA for 60 min
achieved a TIMI flow grade 3 recanalization rate of 60%
(Figs. 2D and 2E). Additionally, the intelligent DDS
ith low-dose tPA attained a significantly higher mean
IMI grade than tPA plus TUS at 30 min and 60 min
1.30  1.16 vs. 0.10  0.32, p  0.01, and 2.00  1.33 vs.
0.50  0.97, p  0.05, respectively) (Fig. 2F).
Figure 3 and the Online Videos 1, 2, and 3 show
epresentative images of coronary angiography at 60 min in
tPA tPA
Figure 3 Coronary Angiography after Thrombolysis
Typical coronary angiographic images at 60 min in swine treated with tPA (55,000
of each affected site. Arrowheads indicate the site of thrombotic occlusion before
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FA in which TUS was not applied.
In the swine injected with 55,000 IU/kg (0.447 mg/kg)
tPA, plasma tPA activity peaked at 30.09  2.82 g/ml
equivalent immediately after injection and decreased
gradually. The plasma tPA activity in swine treated with
55,000 IU/kg (0.447 mg/kg) of tPA plus TUS was
similar. In both groups, the plasma tPA activity in the FA
was similar to that in the LCx at each time point (data
not shown).
The plasma tPA activity immediately after intravenous
injection of the nanoparticles was approximately 75%
lower before TUS application in the LCx and the FA
(8.01  0.89 g/ml and 7.75  1.00 g/ml equivalent,
espectively) than after free tPA injection (30.09  2.82
g/ml and 29.79  1.13 g/ml equivalent, p  0.01)
Fig. 4A). After TUS application for 5 minutes (at 10
inutes), the plasma tPA activity in the LCx in swine
reated with the nanoparticles increased to 32.58  3.04
g/ml equivalent, similar to that immediately after free
PA injection. However, the plasma tPA activity in the
A increased to a much lower level than that in the LCx
18.45  4.41 g/ml equivalent, p  0.01). Treatment
ith the intelligent DDS maintained higher plasma tPA
ctivity in the LCx for up to 30 minutes when compared
ith tPA alone or with tPA plus TUS (Fig. 4A).
The plasma tPA activity in the swine treated with
ow-dose tPA (27,500 IU/kg, 0.2235 mg/kg) is illus-
rated in Figure 4B. The persistently higher plasma tPA
ctivity also was observed in swine treated with the low
ose of tPA, as is the cases with the high dose of tPA
55,000 IU/kg, 0.447 mg/kg). However, in swine treated
ith the intelligent DDS, tPA activity between 10 and 60
in, despite a lower tPA dose, had a similarly shaped
rofile.
eft ventricular ejection fraction after thrombolysis. As
hown in Figure 5, left ventricular ejection fraction at 60
in after thrombolysis in the swine treated with the
ntelligent DDS with 55,000 IU/kg tPA was significantly
igher than in the swine treated with tPA alone (p  0.05)
nd tended to be higher than that in the swine treated with
PA plus TUS.
iscussion
his is the first report of the development and application
f an intelligent DDS for intravenous coronary throm-
olysis comprising tPA, basic gelatin, and zinc ions in a
wine model of AMI. Our DDS is equipped with stealth
ctivity, thrombus targeting, and US-controlled proper-
ies, which enables higher tPA activity at the affected
oronary artery as opposed to the FA, a remote region,
hus enhancing intravenous coronary thrombolysis in a
wine model of AMI. With the present DDS, gelatin
oth covered the active site of tPA and targeted the
anoparticles to the thrombi, probably because of its pbility to bind to vWF, and US helped both to release
PA and to enhance thrombolysis. Thus, the DDS is
ntelligent, unique, and promising.
In our swine model of AMI, treatment with tPA
monteplase) alone could not dissolve any thrombi in
ccluded coronary arteries within 60 min at the dose of
7,500 IU/kg, which achieves approximately 60% recan-
lization in humans (15) and could dissolve only 30% of
hrombi at a dose of 55,000 IU/kg, suggesting our swine
MI model is relatively refractory to conventional
hrombolytic therapy. Even in such a model, the intelli-
ent DDS carrying 55,000 IU/kg and 27,500 IU/kg tPA
ould achieve TIMI flow grade 2 or 3 recanalization in
0% (within 30 min) and in 60% (within 60 min) of cases,
espectively. TIMI flow grade 3 was achieved in 60% of
wine within 30 min by the intelligent DDS carrying
5,000 IU/kg tPA. Additionally, by this thrombolytic
ethod, left ventricular ejection fraction at 60 min was
igher compared with other thrombolytic methods.
hus, the intelligent DDS has much stronger thrombo-
ytic activity than conventional thrombolytic therapy,
hich probably leads to the preservation of cardiac
unction; it is promising in the clinical setting.
During last 2 decades, several investigators used US to
mprove thrombolytic methods without increased bleed-
ng risk. In fact, transcutaneous or transthoracic low-
requency US facilitated thrombolysis in several experi-
ental animal models (5–7), as in the present study (tPA
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Figure 5 Left Ventricular Ejection Fraction in
Swine Acute Myocardial Infarction Model
Left ventricular ejection fraction (LVEF) at 60 min in swine treated with 55,000 IU/kg
of tPA (*p  0.05 vs. tPA alone). Abbreviations as in Figures 1 and 2.lus TUS group in Fig. 2). However, in a double-blind,
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of 396 patients with ST-segment elevation myocardial
infarction, thrombolytic agents plus low-frequency trans-
cutaneous US failed to improve TIMI flow grade and
ST-segment resolution at 60 min versus a thrombolytic
agent alone (8).
Recently, we reported that nanoparticles comprising tPA,
cationized gelatin, and anionic gelatin with polyethylene
glycol suppressed tPA activity by approximately 55%, but
this activity was fully recovered by US application (13). In
the present study, we formed a new generation of nanopar-
ticles comprising gelatin and tPA in the presence of zinc
ions (5 mM), in which tPA activity was reduced to
approximately 50% in vitro and to 25% to 30% in vivo of the
equivalent dose of free tPA, and that was fully recovered by
US application. It is well known that US exerts the effect of
cavitation on tissue liquid, which induces an intense local
pressure (16). This pressure would enable the dissociation of
tPA from nanoparticles and would allow tPA to exert
biological action. As shown in Online Figure 6 and Online
Table 1, only injection of nanoparticles without US appli-
cation had little effect on the thrombus in the rabbit arterial
thrombosis model, whereas TIMI flow grade 2 and 3
recanalization was observed in 5 of 10 rabbits with injection
of the same dose of free tPA. However, with transcutaneous
US application, the nanoparticles recanalized the FA oc-
cluded by thrombus in all 10 rabbits within 30 min. These
data suggests the tPA activity of the nanoparticles was
suppressed and recovered by transcutaneous US application
in vivo.
Another important issue is the development of a new
device for TUS application. The new device, comprising 4
probes of 1.0 MHz in parallel (Online Fig. 1), created
uniform US fields over the entire heart, as quantified by a
catheter-type oscilloscope inserted into the left ventricle,
right coronary artery, left anterior descending coronary
artery, and LCx, as shown in Online Figure 2. Thus, it may
lead to feasible release of tPA and favorable US-related
effects, such as cavitation and drug permeation into the clot
in any coronary artery.
In terms of safety, gelatin and zinc acetate have proven
biosafety profiles because of their longstanding use in
medical materials such as drug ingredients (17–19). We also
investigated the direct effects of US on apoptosis and
inflammation. As shown in Online Figure 7, gene expres-
sion of apoptotic and inflammatory markers was not in-
duced by transcutaneous or transthoracic US applications
for 60 min. These findings suggest that the present intelli-
gent DDS is promising in the clinical setting.
Conclusions
In summary, we developed for the first time a US-
controlled DDS for coronary thrombolysis with both
stealth activity of thrombolytic agents and thrombus-
targeting properties and demonstrated its efficacy inthrombolysis in a swine model of AMI. Our intelligent
DDS may provide novel reperfusion therapy in AMI
patients that theoretically can be started in an ambulance
and is also applicable in the treatment of stroke, pulmo-
nary thromboembolism, peripheral arterial thrombosis,
and leg vein thrombosis.
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APPENDIX
For a supplemental Methods section, and supplemental figures, tables,
references, and videos, please see the online version of this article.
